SuperworthKrystal Biotech EV/EBIT KRYS
Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2024.
- Today, Oct 23, 2026
- 42.4×
- 2-year median
- 42.3×
- Against its 2-year history
- 51st
- percentile: 0 is its lowest day, 100 its highest
- 2-year range
- 17.6× to 317×
- Peer median
- 17.8×
Krystal Biotech's EV/EBIT is 42.4× as of Oct 23, 2026.
That is above its 2-year median of 42.3×, close to the middle of its last 2 years.
Over that time it ranged from 17.6× in May 2025 to 317× in Aug 2024.
The median for 10 biotech stocks of a similar size is 17.8×.
EV/EBIT over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 42.4× | 32.9× | 57.3× |
| 2025 | 33.6× | 17.6× | 51.8× |
| 2024 | 51.6× | 51.6× | 317× |
Against its peers
Companies in Biotechnology nearest Krystal Biotech's size, closest first, today.
| Company | EV/EBIT |
|---|---|
| KRYSKrystal Biotech | 42.4× |
| RGENRepligen | 160× |
| TECHBIO-TECHNE | 44.9× |
| HALOHalozyme Therapeutics | 17.4× |
| NBIXNeurocrine Biosciences | 18.2× |
| EXELExelixis | 15.4× |
| INCYIncyte | 10.1× |
| UTHRUnited Therapeutics | 16.1× |
| ALNYAlnylam Pharmaceuticals | 27.9× |
| ADMAAdma Biologics | 10.9× |
| VCELVericel | 116× |
| Peer median | 17.8× |
Where Krystal Biotech ranks
What the EV/EBIT tells you
What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.
Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.
More on Krystal Biotech
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.